10079-78-4

Upstream product

• 3240-35-5 4-formyl-benzenesulfonamide 
• 2537-48-6 diethyl 1-cyanomethylphosphonate 
• 477259-57-7 4-[3-(2,2,2-trifluoro-acetylamino)propyl]benzenesulfonyl chloride 
• 2038-57-5 3-Phenylpropan-1-amine 
• 77970-72-0 2,2,2-trifluoro-N-(3-phenyl-propyl)acetamide 

Downstream Products

• 121626-16-2 2,6,6-trimethyl-4-oxo-1-<3-(4-sulfonamido)phenyl-n-propyl>-4,5,6,7-tetrahydroindole-3-acetic acid 

Relevant academic research and scientific papers

1,3-disubstituted urea derivatives, optical isomer thereof, or pharmaceutically acceptable salts thereof, and a pharmaceutical composition for preventing or treating cardiovascular disease comprising the same as an active ingredient

The present invention relates to a 1,3-disubstituted urea derivative compound, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for preventing or treating cardiovascular disorders containing the same as an active ingredient. The 1,3-disubstituted urea derivative compound excellently suppresses soluble epoxide hydrolase (sEH), and thus effectively blocks a metabolic pathway for epoxyeicosatrienoic acid (EET) to become dihydroxyeicosatrienoic acid (DHET), thereby being useful as pharmaceutical compositions for preventing or treating cardiovascular disorders.(AA) Positive control group(BB) Example 2-1(CC) Example 2-2(DD) Example 2-1(EE) Example 2-4(FF) Example 2-5(GG) Example 2-6(HH) Example 2-7(II) Example 2-8(JJ) Example 2-9(KK) Example 2-10(LL) Example 2-11(MM) Example 2-12(NN) Example 2-13(OO) Example 2-14(PP) Example 2-15(QQ) Example 2-16(RR) Example 2-17(SS) Example 2-18(TT) Example 2-19(UU) Example 2-20(VV) Example 2-21(WW) Example 2-22(XX) Example 2-23(YY) Example 2-24(Z1) Example 2-25(Z2) Example 2-26COPYRIGHT KIPO 2017

Discovery of enantioselectivity of urea inhibitors of soluble epoxide hydrolase

Soluble epoxide hydrolase (sEH) hydrolyzes epoxyeicosatrienoic acids (EETs) in the metabolic pathway of arachidonic acid and has been considered as an important therapeutic target for chronic diseases such as hypertension, diabetes and inflammation. Although many urea derivatives are known as sEH inhibitors, the enantioselectivity of the inhibitors is not highlighted in spite of the stereoselective hydrolysis of EETs by sEH. In an effort to explore the importance of enantioselectivity in the urea scaffold, a series of enantiomers with the stereocenter adjacent to the urea nitrogen atom were prepared. The selectivity of enantiomers of 1-(α-alkyl-α-phenylmethyl)-3-(3-phenylpropyl)ureas showed wide range differences up to 125 fold with the low IC50 value up to 13 nM. The S-configuration with planar phenyl and small alkyl groups at α-position is crucial for the activity and selectivity. However, restriction of the free rotation of two α-groups with indan-1-yl or 1,2,3,4-tetrahydronaphthalen-1-yl moiety abolishes the selectivity between the enantiomers, despite the increase in activity up to 13 nM. The hydrophilic group like sulfonamido group at para position of 3-phenylpropyl motif of 1-(α-alkyl-α-phenylmethyl-3-(3-phenylpropyl)urea improves the activity as well as enantiomeric selectivity. All these ureas are proved to be specific inhibitor of sEH without inhibition against mEH.

Aziridine and phenethanolamine derivatives having antiobesity and anti-hyperglycaemic acitivity

Aziridine and phenethanolamine derivatives of formulae I and II-1 STR1 wherein R1 and R2 are hydrogen or lower-alkyl; Z1 is phenyl or a phenyl group substituted in a defined manner; Z2 and Z21 are phenyl or thienyl substituted in a defined manner; and, n is an integer from 1-4. The disclosed compounds have catabolic activity and can be used for the treatment of obesity and/or of sugar illnesses. The compounds of formula I are obtained by dehydrating β-aminoalcohols (e.g. those of formula II-1) which, in turn, can be prepared by adding amines to epoxides or by reducing corresponding iminoketones, iminoalcohols a-keto-β-hydroxyamines or β-ketoamines.